Rigel Pharmaceuticals
NASDAQ:RIGL 1:00:00 PM EDT
| Market Cap (Intraday) | 338.32M |
| Current PE | 9.10 |
| Forward PE | 16.9 |
| 2yr Forward PE | 11.83 |
| 10-Day MA | $19.03 |
| 50-Day MA | $19.51 |
| 200-Day MA | $19.04 |
Rigel Pharmaceuticals Stock, NASDAQ:RIGL
611 Gateway Boulevard, Suite 900, South San Francisco, California 94080-1985
United States of America
Phone: +1.650.624.1100
Number of Employees: 164
Description
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.